These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 32488129)

  • 1. The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimers disease.
    Pentz R; Iulita MF; Ducatenzeiler A; Bennett DA; Cuello AC
    Mol Psychiatry; 2021 Oct; 26(10):6023-6037. PubMed ID: 32488129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new role for matrix metalloproteinase-3 in the NGF metabolic pathway: Proteolysis of mature NGF and sex-specific differences in the continuum of Alzheimer's pathology.
    Pentz R; Iulita MF; Mikutra-Cencora M; Ducatenzeiler A; Bennett DA; Cuello AC
    Neurobiol Dis; 2021 Jan; 148():105150. PubMed ID: 33130223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study.
    Pentz R; Iulita MF; Ducatenzeiler A; Videla L; Benejam B; Carmona‐Iragui M; Blesa R; Lleó A; Fortea J; Cuello AC
    Alzheimers Dement; 2021 Apr; 17(4):605-617. PubMed ID: 33226181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nerve growth factor metabolic dysfunction in Down's syndrome brains.
    Iulita MF; Do Carmo S; Ower AK; Fortress AM; Flores Aguilar L; Hanna M; Wisniewski T; Granholm AC; Buhusi M; Busciglio J; Cuello AC
    Brain; 2014 Mar; 137(Pt 3):860-72. PubMed ID: 24519975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NGF-cholinergic dependency in brain aging, MCI and Alzheimer's disease.
    Cuello AC; Bruno MA; Bell KF
    Curr Alzheimer Res; 2007 Sep; 4(4):351-8. PubMed ID: 17908036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer's Disease.
    Counts SE; He B; Prout JG; Michalski B; Farotti L; Fahnestock M; Mufson EJ
    Curr Alzheimer Res; 2016; 13(7):800-8. PubMed ID: 26825093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hippocampal proNGF signaling pathways and β-amyloid levels in mild cognitive impairment and Alzheimer disease.
    Mufson EJ; He B; Nadeem M; Perez SE; Counts SE; Leurgans S; Fritz J; Lah J; Ginsberg SD; Wuu J; Scheff SW
    J Neuropathol Exp Neurol; 2012 Nov; 71(11):1018-29. PubMed ID: 23095849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease.
    Peng S; Wuu J; Mufson EJ; Fahnestock M
    J Neuropathol Exp Neurol; 2004 Jun; 63(6):641-9. PubMed ID: 15217092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Nerve Growth Factor Metabolic Pathway Dysregulation as Cause of Alzheimer's Cholinergic Atrophy.
    Do Carmo S; Kannel B; Cuello AC
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resilience of precuneus neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer's disease.
    Perez SE; He B; Nadeem M; Wuu J; Scheff SW; Abrahamson EE; Ikonomovic MD; Mufson EJ
    Biol Psychiatry; 2015 Apr; 77(8):693-703. PubMed ID: 24529280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Brain NGF Metabolic Pathway in Health and in Alzheimer's Pathology.
    Cuello AC; Pentz R; Hall H
    Front Neurosci; 2019; 13():62. PubMed ID: 30809111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased matrix metalloproteinase 9 activity in mild cognitive impairment.
    Bruno MA; Mufson EJ; Wuu J; Cuello AC
    J Neuropathol Exp Neurol; 2009 Dec; 68(12):1309-18. PubMed ID: 19915485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preservation of cortical sortilin protein levels in MCI and Alzheimer's disease.
    Mufson EJ; Wuu J; Counts SE; Nykjaer A
    Neurosci Lett; 2010 Mar; 471(3):129-33. PubMed ID: 20085800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential deregulation of NGF and BDNF neurotrophins in a transgenic rat model of Alzheimer's disease.
    Iulita MF; Bistué Millón MB; Pentz R; Aguilar LF; Do Carmo S; Allard S; Michalski B; Wilson EN; Ducatenzeiler A; Bruno MA; Fahnestock M; Cuello AC
    Neurobiol Dis; 2017 Dec; 108():307-323. PubMed ID: 28865749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender differences in neurotrophin and glutamate receptor expression in cholinergic nucleus basalis neurons during the progression of Alzheimer's disease.
    Counts SE; Che S; Ginsberg SD; Mufson EJ
    J Chem Neuroanat; 2011 Oct; 42(2):111-7. PubMed ID: 21397006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rita Levi-Montalcini, NGF Metabolism in Health and in the Alzheimer's Pathology.
    Cuello AC
    Adv Exp Med Biol; 2021; 1331():119-144. PubMed ID: 34453296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholinergic involvement in Alzheimer's disease. A link with NGF maturation and degradation.
    Cuello AC; Bruno MA; Allard S; Leon W; Iulita MF
    J Mol Neurosci; 2010 Jan; 40(1-2):230-5. PubMed ID: 19680822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. proNGF Involvement in the Adult Neurogenesis Dysfunction in Alzheimer's Disease.
    Olabiyi BF; Fleitas C; Zammou B; Ferrer I; Rampon C; Egea J; Espinet C
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the NGF maturation and degradation pathway on the cortical cholinergic system phenotype.
    Allard S; Leon WC; Pakavathkumar P; Bruno MA; Ribeiro-da-Silva A; Cuello AC
    J Neurosci; 2012 Feb; 32(6):2002-12. PubMed ID: 22323714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ProNGF and Neurodegeneration in Alzheimer's Disease.
    Fahnestock M; Shekari A
    Front Neurosci; 2019; 13():129. PubMed ID: 30853882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.